PREDICTING IMMUNE-RELATED ADVERSE EVENTS DURING CANCER IMMUNOTHERAPY AND THE LIKE

摘要

The present invention primarily addresses the problem of discovering a means for predicting the risk (especially the risk of onset or exacerbation of problematic pulmonary disorders occurring as adverse events during cancer immunotherapy or the like) of onset of pulmonary disorders as typified by interstitial pneumonia, especially idiopathic interstitial pneumonia, and to facilitate the use and application thereof. Provided are: a pulmonary disorder biomarker constituted by anti-GPRC5A antibodies or HLA-A2402-restricted GPRC5A peptide-specific cytotoxic T cells; and various applications that utilize the same.